Quantx Biosciences closed an oversubscribed $85 million Series B to advance two oral small‑molecule immunology candidates into the clinic: a STAT6 inhibitor and an IL‑17 inhibitor. The financing will fund IND‑enabling work and early‑stage clinical programs, the company said. Quantx emphasized its discovery platform that blends physics‑based modeling with statistical and computational chemistry to generate oral candidates for immunologic targets. The raise signals investor interest in oral small‑molecule approaches to immunology that could offer differentiated safety and dosing profiles versus biologics.